Use of gemtuzumab ozogamicin in the treatment of pediatric relapsed/refractory acute myeloid leukemia

Turkish Journal of Hematology

Volumn 25, Issue 1, 2008, Pages 36-41

  Ünal, Elif ^a   Sahdev, Indira ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Gemtuzumab ozogamicin; Mylotarg; Pediatric acute myeloid leukemia; Sinusoidal obstruction syndrome; Veno occlusive disease

Indexed keywords

ANTIBIOTIC AGENT; AZACITIDINE; CD33 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DIPHENHYDRAMINE; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; HEPARIN; IDARUBICIN; PARACETAMOL;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLOOD PRESSURE; BLOOD TOXICITY; CARDIOTOXICITY; CHILD; CHILDHOOD LEUKEMIA; CHILL; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG FEVER; DRUG RESPONSE; FATALITY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOTENSION; HYPOXIA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER VENOOCCLUSIVE DISEASE; LUNG INFILTRATE; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NEUROTOXICITY; NONMYELOABLATIVE CONDITIONING; RESPIRATORY TRACT EXAMINATION; SIDE EFFECT; SINGLE DRUG DOSE; WHOLE BODY RADIATION;

EID: 44949225412     PISSN: 13007777     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001;97:56-62.
2. Creutzig U, Berthold F, Boos J, et al. [Improved treatment results in children with AML: results of study AML-BFM 931]. Klin Padiatr 2001;213:175-85.
3. Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol 1998;101:130-40.
4. Vignetti M, Orsini E, Petti MC, et al. Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: a single-centre experience. Ann Oncol 1996;7:933-8.
5. Webb DK. Management of relapsed acute myeloid leukaemia. Br J Haematol 1999;106:851-9.
6. Griffin JD, Linch D, Sabbath K, Larcom P, Schlossman SF. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res 1984;8:521-34.
7. Hamann PR, Hinman LM, Beyer CF, et al. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem 2002;13:40-6.
8. Zein N, Sinha AM, McGahren WJ, Ellestad GA. Calicheamicin gamma II: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 1988;240:1198-201.
9. Nicolaou KC, Smith AL, Yue EW. Chemistry and biology of natural and designed enediynes. Proc Natl Acad Sci USA 1993;90:5881-8.
10. Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999;93:3678-84.
11. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. Clin Oncol 2001;19:3244-54.
12. Giles FJ, Kantarjian HM, Kornblau SM, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001;92:406-13.
13. Neumeister P, Eibl M, Zinke-Cerwenka W, Scarpatetti M, Sill H, Linkesch W. Hepatic veno-occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin (CMA-676) immunoconjugate. Ann Hematol 2001;80:119-20.
14. Zwaan CM, Reinhardt D, Corbacioglu S, et al. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. Blood 2003;101:3868-871.
15. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993;118:255-67.
16. Arceci JA, Sande J, Lange B, Shannon K, Franklin J, Hutchinson R, Vik AT, Flowers D, Apleric R, Berger SM, Sherman LM, Smith OF, Bernstein I, Sievers E. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood 2005;106:1183-8.
17. Brethon B, Auvrignon A, Galambrun C, Yakouben K, Leblanc T, Bertrand Y, Leverger G, Baruchel A. Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia. BMC Cancer 2006;6:172.
18. Wadleigh M, Ho V, Momtaz P, Richardson P. Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment. Curr Opin Hematol 2003;10:451-62.
19. Versluys B, Bhattacharaya R, Steward C, Cornish J, Oakhill A, Goulden N. Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure. Blood 2004;103:1968.